Peptides as cancer vaccines

Tardón, Marta Calvo; Allard, Mathilde; Dutoit, Valérie; Dietrich, Pierre‐Yves; Walker, Paul R

doi:10.1016/j.coph.2019.01.007

Cited by 76 publications

(54 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While peptide vaccines are generally deemed safe and well tolerated, their clinical efficacy has not been as exciting as that of other immunotherapies, such as immune checkpoint inhibitors . Nonetheless, major advances in the selection of tumor antigens, identification of epitopes binding to HLA molecules, and integration of these into peptides for formulation into a vaccine have been achieved …”

Section: Immunotherapeutic and Immunomodulatory Agents In Phggmentioning

confidence: 99%

“…Additionally, antigen vaccines using protein, protein subunits, DNA, or RNA have also been exploited to induce responses in cancer patients by stimulating tumor-specific T cells and immunological memory. 97,98 While peptide vaccines are generally deemed safe and well tolerated, their clinical efficacy has not been as exciting as that of other immunotherapies, such as immune checkpoint inhibitors. 97,98 Nonetheless, major advances in the selection of tumor antigens, identification of epitopes binding to HLA molecules, and integration of these into peptides for formulation into a vaccine have been achieved.…”

Section: Vaccines and Antigen Vaccinesmentioning

confidence: 99%

“…97,98 While peptide vaccines are generally deemed safe and well tolerated, their clinical efficacy has not been as exciting as that of other immunotherapies, such as immune checkpoint inhibitors. 97,98 Nonetheless, major advances in the selection of tumor antigens, identification of epitopes binding to HLA molecules, and integration of these into peptides for formulation into a vaccine have been achieved. 98 Ongoing trials with antigen vaccines include a pilot study evaluating glioma-associated antigen vaccines in conjunction with poly-ICLC in pediatric gliomas (NCT01130077); a phase I trial with the Heat Shock Protein Peptide Complex-96 (HSPPC-96) vaccine in children with newly diagnosed and recurrent HGG and recurrent ependymomas (NCT02722512); and a phase I trial with cytomegalovirus (CMV)specific peptide vaccine (PEP-CMV) in children with recurrent HGG and medulloblastomas (NCT03299309).…”

Section: Vaccines and Antigen Vaccinesmentioning

confidence: 99%

“…97,98 Nonetheless, major advances in the selection of tumor antigens, identification of epitopes binding to HLA molecules, and integration of these into peptides for formulation into a vaccine have been achieved. 98 Ongoing trials with antigen vaccines include a pilot study evaluating glioma-associated antigen vaccines in conjunction with poly-ICLC in pediatric gliomas (NCT01130077); a phase I trial with the Heat Shock Protein Peptide Complex-96 (HSPPC-96) vaccine in children with newly diagnosed and recurrent HGG and recurrent ependymomas (NCT02722512); and a phase I trial with cytomegalovirus (CMV)specific peptide vaccine (PEP-CMV) in children with recurrent HGG and medulloblastomas (NCT03299309). Three first-in-human CAR T-cell trials targeting IL13R 2, HER2/CMV, and EGFRvIII, respectively, reported objective radiologic responses in adults and children with relapsed glioblastomas.…”

Section: Vaccines and Antigen Vaccinesmentioning

confidence: 99%

See 3 more Smart Citations

Challenging the indiscriminate use of temozolomide in pediatric high‐grade gliomas: A review of past, current, and emerging therapies

Guerra‐García

Marshall

Cockle

et al. 2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Pediatric high‐grade gliomas (pHGG) constitute 8% to 12% of primary brain tumors in childhood. The most widely utilized treatment encompasses surgical resection followed by focal radiotherapy and temozolomide. However, experiences over past decades have not demonstrated improved outcomes. pHGG have been classified into different molecular subgroups defined by mutations in histone 3, IDH gene, MAPK pathway, and others, thereby providing a rationale for various targeted therapies. Additionally, immunotherapy and drug repurposing have also become attractive adjunctive treatments. This review focuses on past, present, and emerging treatments for pHGG integrating molecular research with the mainstream pediatric drug development in Europe and the United States to sketch a way forward in the development of novel therapeutic approaches. The implementation of randomized clinical trials with adaptive designs, underpinned by a robust biological rationale, and harnessing collaboration between the pharmaceutical industry, academia, regulators and patients/parents organizations will be essential to improve the outcomes for these children.

show abstract

Section: Immunotherapeutic and Immunomodulatory Agents In Phggmentioning

confidence: 99%

Section: Vaccines and Antigen Vaccinesmentioning

confidence: 99%

Section: Vaccines and Antigen Vaccinesmentioning

confidence: 99%

Section: Vaccines and Antigen Vaccinesmentioning

confidence: 99%

See 2 more Smart Citations

Challenging the indiscriminate use of temozolomide in pediatric high‐grade gliomas: A review of past, current, and emerging therapies

Guerra‐García

Marshall

Cockle

et al. 2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Among those distinct approaches of therapeutic vaccines, peptide-based vaccination is a highly desirable strategy and has gained increasing attentions [18,19]. Peptide-based vaccines are aimed at precisely inducing immune response against antigens by key epitope peptides but not the entire antigen and thus have several advantages over traditional vaccines such as higher specificity, higher safety, lower costs, and less adverse events [19][20][21]. Studies in recent years have suggested that peptidebased vaccinations are promising in treating diseases such as cancer and allergic diseases, and some have shown impressive clinical benefits [22][23][24].…”

Section: Introductionmentioning

confidence: 99%

Peptide-Based Vaccination Therapy for Rheumatic Diseases

Wang

Chen

Zheng

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

Rheumatic diseases are extremely heterogeneous diseases with substantial risks of morbidity and mortality, and there is a pressing need in developing more safe and cost-effective treatment strategies. Peptide-based vaccination is a highly desirable strategy in treating noninfection diseases, such as cancer and autoimmune diseases, and has gained increasing attentions. This review is aimed at providing a brief overview of the recent advances in peptide-based vaccination therapy for rheumatic diseases. Tremendous efforts have been made to develop effective peptide-based vaccinations against rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), while studies in other rheumatic diseases are still limited. Peptide-based active vaccination against pathogenic cytokines such as TNF-α and interferon-α (IFN-α) is shown to be promising in treating RA or SLE. Moreover, peptide-based tolerogenic vaccinations also have encouraging results in treating RA or SLE. However, most studies available now have been mainly based on animal models, while evidence from clinical studies is still lacking. The translation of these advances from experimental studies into clinical therapy remains impeded by some obstacles such as species difference in immunity, disease heterogeneity, and lack of safe delivery carriers or adjuvants. Nevertheless, advances in high-throughput technology, bioinformatics, and nanotechnology may help overcome these impediments and facilitate the successful development of peptide-based vaccination therapy for rheumatic diseases.

show abstract

Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy

et al. 2021

View full text Add to dashboard Cite

The discovery of immune checkpoint blockade has revolutionized the field of immuno‐oncology and established the foundation for developing various new therapies that can surpass conventional cancer treatments. Most recent immunotherapeutic strategies have focused on adaptive immune responses by targeting T cell‐activating pathways, genetic engineering of T cells with chimeric antigen receptors, or bispecific antibodies. Despite the unprecedented clinical success, these T cell‐based treatments have only benefited a small proportion of patients. Thus, the need for the next generation of cancer immunotherapy is driven by identifying novel therapeutic molecules or new immunoengineered cells. To maximize the therapeutic potency via innate immunogenicity, the convergence of innate immunity‐based therapy and biomaterials is required to yield an efficient index in clinical trials. This review highlights how biomaterials can efficiently reprogram and recruit innate immune cells in tumors and ultimately initiate activation of T cell immunity against advanced cancers. Moreover, the design and specific biomaterials that improve innate immune cells’ targeting ability to selectively activate immunogenicity with minimal adverse effects are discussed.

show abstract

Peptides as cancer vaccines

Cited by 76 publications

References 62 publications

Challenging the indiscriminate use of temozolomide in pediatric high‐grade gliomas: A review of past, current, and emerging therapies

Challenging the indiscriminate use of temozolomide in pediatric high‐grade gliomas: A review of past, current, and emerging therapies

Peptide-Based Vaccination Therapy for Rheumatic Diseases

Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy

Contact Info

Product

Resources

About